BioSpace News Archive

HeartBeam, Inc. announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the United States Patent and Trademark Office.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that ASTRUM-005, an international multi-centre study led by Professor Ying Cheng, has been published in The Journal of the American Medical Association (JAMA, impact factor of 157.3), one of the top four medical journals in the world.

Brand Institute is proud to announce its work with Heron Therapeutics in developing the brand name APONVIE™, which was approved by the FDA September 16, 2022.

Point Robotics MedTech Inc. (Point Robotics), a rising star in the field of orthopedic surgery, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its minimally invasive surgical robot, POINT™ Kinguide Robotic-Assisted Surgical System, in August.

iuvo BioScience today announced it has signed a definitive agreement to be acquired by Ampersand Capital Partners.

Fore Biotherapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to FORE8934, its investigational, novel, small-molecule, orally available inhibitor for the treatment of patients with cancers harboring BRAF Class 1 (V600) and Class 2 (including fusions) alterations who have exhausted prior therapies.

Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that the Company’s comprehensive procedural solutions will be featured at the North American Spine Society (NASS) 37th Annual Meeting, which will be held at the McCormick Place West Building from October 12 - 15, 2022.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist.

CurvaFix, Inc ., a developer of medical devices to repair fractures in curved bones, today announced the addition of three new members to its Surgeon Advisory Board.

Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that has emerged from stealth today.